BioSyent Announces Renewal of Normal Course Issuer Bid

MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 800,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.1% of the Shares outstanding as of December 15, 2025.